Preemptive strategy for ganciclovir administration against cytomegalovirus in liver transplantation recipients

American Journal of Transplantation

Volumn 2, Issue 10, 2002, Pages 955-958

  Daly, Jennifer S ^a   Kopasz, Andrea ^a   Anandakrishnan, Raji ^a   Robins, Terry ^b   Mehta, Savant ^b   Halvorsen, Michelle ^a   Katz, Eliezer ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

Cytomegalovirus infection; Liver transplantation; Preemptive strategy

Indexed keywords

ACICLOVIR; GANCICLOVIR; OKT 3; STEROID; TACROLIMUS;

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG COST; DRUG EFFICACY; GRAFT REJECTION; HERPES; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; COSTS AND COST ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; INJECTIONS, INTRAVENOUS; LIVER TRANSPLANTATION; MASSACHUSETTS; MONITORING, PHYSIOLOGIC; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 0344837778     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2002.21012.x     Document Type: Article

References (15)

1. Couchoud C, Cucherat M, Haugh M et al. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis. Transplantation 1998; 65: 641-647.
2. Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 2001; 32: 742-751.
3. Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000; 13: 83-121.
4. Paya CV. Prevention of cytomegalovirus disease in recipients of solid-organ transplants. Clin Infect Dis 2001; 32: 596-603.
5. Limaye AP, Corey L, Koelle DM et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645-649.
6. Kusne S, Shapiro R, Fung J. Prevention and treatment of cytomegalovirus infection in organ transplant recipients. Transpl Infect Dis 1999; 1: 187-203.
7. Sia IG, Wilson JA, Groettum CM et al. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000; 181: 717-720.
8. Kusne S, Grossi P, Irish W et al. Cytomegalovirus pp65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1999; 68: 1125-1131.
9. Humar A, Gregson D, Caliendo AM et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999; 68: 1305-1311.
10. Gane E, Saliba F, Valdecasas GJ et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The oral ganciclovir international transplantation study group. Lancet 1997; 350: 1729-1733.
11. Kim WR, Badley AD, Wiesner RH et al. The economic impact of cytomegalovirus infection after liver transplantation. Transplantation 2000; 69: 357-361.
12. Paya CV, Wilson JA, Espy MJ et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185: 854-860.
13. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International valacyclovir cytomegalovirus prophylaxis transplantation study group. N Engl J Med 1999; 340: 1462-1470.
14. Singh N, Yu VL, Mieles L et al. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann Intern Med 1994; 120: 375-381.
15. Vivarelli M, De Ruvo N, Lazzarotto T et al. Abstention from treatment of low-level pp65 cytomegalovirus antigenemia after liver transplantation: a prospective study. Transplantation 2000; 70: 1183-1187.